SEC Form 4 · accession 0001144204-19-002683
Neurotrope, Inc. · NTRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel L. Alkon
Officer — See Remarks
Period of report
Jan 22, 2019
Accepted (ET)
Jan 24, 2019 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001513856
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.93 | Jan 22, 2019 | A | 150,000 | A | — | Jan 22, 2029 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The stock option award was made pursuant to the terms of the Neurotrope, Inc. 2017 Equity Incentive Plan. The stock options shall vest according to the following schedule: 50% vest on the date of grant, with the remaining stock options vesting in equal quarterly installments over a two-year period following the date of grant.
Remarks
President, Chief Scientific Officer